.png "Charles River Labs (NYSE: CRL)")
In a report released today, Donald Hooker from KeyBanc upgraded Charles River Labs (NYSE: CRL) to Buy. The company’s shares closed yesterday at $114.47.
According to TipRanks.com, Hooker is a 5-star analyst with an average return of 15.4% and a 77.4% success rate. Hooker covers the Services sector, focusing on stocks such as Quest Diagnostics Inc, Laboratory Corp, and Evolent Health.
Charles River Labs has an analyst consensus of Moderate Buy, with a price target consensus of $122.
See today’s analyst top recommended stocks >>
The company has a one-year high of $119.05 and a one-year low of $94.15. Currently, Charles River Labs has an average volume of 288.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions.
